CX 397

Drug Profile

CX 397

Latest Information Update: 16 Nov 2006

Price : $50

At a glance

  • Originator Nikko Kyodo
  • Developer Japan Energy Corporation; Nikko Kyodo
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary thrombosis; Disseminated intravascular coagulation; Thrombosis

Most Recent Events

  • 09 Apr 1999 A preclinical study has been added to the Thromboses pharmacodynamics sections
  • 22 Mar 1999 A study has been added to the Thromboses therapeutic trials section
  • 22 Mar 1999 A preclinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top